Now, they share the recommendations of the other medical societies that do not call for stopping the medication
Phase 3 results are needed No cardiovascular outcomes data available The biased signaling mechanism, while promising, needs long-term validation Exact molecular structure has not been publicly disclosed Phase 3 trials are planned but not yet enrolled Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity , published in Cell Metabolism (Roche/Genentech/Carmot Therapeutics investigators, 2025
GLP-1R antagonist Exendin(939) (Tocris, Ex(939), 50 g/kg, i.v.) or vehicle control was administered 40 min before the onset of coronary ischaemia
It may aid in fat metabolism, helping the body process fats and carbohydrates more efficiently
Improved quality of life: Due to the potential for durable responses and fewer severe side effects, immunotherapies can contribute to an improved quality of life for GI cancer patients
.png.jpg)
